Revision as of 10:16, 1 August 2015 by Rossdonaldson1 (talk | contribs) (Sources)


Adult Dosing


  • PO: 20-40 mg q8hr, or 30-60mg (extended release) q12hr
  • IV: 5 mg/hr by slow infusion (50 ml/hr), titrate to maximum of 30 mg/hr, then maintenance of 2.0 - 15.5 mg/hr
  • IV bolus dose of 2 mg, then continuous infusion achieves same control of HTN as starting infusion without bolus[1]

Chronic Stable Angina

  • 20-40 mg PO q8hr
  • Allow 3 days between dose increase

Pediatric Dosing


  • 0.5-3 mcg/kg/min IV
  • Not approved by FDA; limited date available

Special Populations

  • Pregnancy Rating: Category C
  • Lactation: Unknown wether drug is excreted in breast milk; avoid use
  • Renal Dosing
    • Adult
    • Pediatric
  • Hepatic Dosing
    • Adult
    • Pediatric


  • Allergy to class/drug

Adverse Reactions




  • Half-life: 2-4 hr
  • Metabolism: Metabolized in liver b CYP3A4 (first pass)
  • Excretion: urine (60%), feces (35%)
  • Mechanism of Action:
    • inhibits trasmembrane influx of extracellular calcium ions across membranes of myocardial cells and vascular smooth muscle cells without changing serum calcium concentrations; this inhibit cardiac and vascular smooth muscle contractions, thereby dilating maincoronary and systemic arteries.

See Also


  1. Tao P, Zheng DY, Yu XJ. Effects of intravenous nicardipine in Chinese patients with hypertensive emergencies. Curr Ther Res Clin Exp 1998 Mar; 59: 188-95.